TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00538642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
Study: NCT01608152

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Attend a focus group

Intervention type: OTHER
Intervention: Internet-Based Intervention
Description: Have access to the game

Intervention type: BEHAVIORAL
Intervention: Interview
Description: 1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
Study: NCT01816087

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brief geriatric assessment
Description: All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
Study: NCT03411551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia
Description: The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
Study: NCT04546698

Intervention type: OTHER
Intervention: blood sampling
Description: Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group

Intervention type: OTHER
Intervention: blood sampling
Description: Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group

Intervention type: OTHER
Intervention: blood sampling
Description: Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group
Study: NCT02053116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Tablet, 200 mg, twice daily, 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg, twice daily, 2 weeks
Study: NCT02406612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-Seal 6F Vascular Closure Device
Study: NCT03737227

Intervention type: RADIATION
Group type: OTHER
Intervention: Cinematographic recording
Description: Cinematographic recording during flexion and extension of the lumbar spine.
Study: NCT02363660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GINI
Study: NCT00297414

Intervention type: OTHER
Intervention: No intervention
Description: No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
Study: NCT02363660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GINI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GINI
Study: NCT03022214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
Study: NCT01812980

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine
Description: WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.
Study: NCT01673347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meniscal Allograft
Description: Meniscal allograft
Study: NCT02719873

Intervention type: OTHER
Intervention: The impact of maternal obesity on pregnancy outcomes
Description: observation of maternal obesity effect in foetal and maternal outcome
Study: NCT00649311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
Study: NCT03560739

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ofatumumab with PRF
Description: ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ofatumumab with PRF
Description: ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ofatumumab with AI
Description: ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ofatumumab with AI
Description: ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
Study: NCT01936740

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Study: NCT04474730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMT Physical Activity app
Description: This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
Study: NCT03544788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cirvo™ Therapy
Description: The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
Study: NCT04474730

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watch Only
Description: A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
Study: NCT04093830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid
Description: hearing aid can be used in their non- implanted ear with residual hearing
Study: NCT00559832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Exposure
Description: Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
Study: NCT02368925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy™ System
Description: The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200\~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
Study: NCT00177047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Mesna
Description: Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered intravenously 200 mg/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Description: Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
Study: NCT01787344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A(Botox®)
Description: Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A(Botulax®)
Description: Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
Study: NCT03505827

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-2 SITA Standard Humphrey Visual Field Test
Description: Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
Study: NCT04769557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: tablet paracetamol 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00576680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Given orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Taken orally once a day for one week followed by a one-week break period
Study: NCT02230527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg twice a day by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg once a day by mouth
Study: NCT01011478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04643301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector
Description: Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
Study: NCT03671278

Intervention type: OTHER
Group type: OTHER
Intervention: STarT Back Screening Tool Approach
Description: Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
Study: NCT04461600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL101
Description: AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
Study: NCT03933995

Intervention type: OTHER
Intervention: no Intervention
Description: no Intervention
Study: NCT04403009

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03014882

Intervention type: DRUG
Group type: OTHER
Intervention: L-Carnitine and N-acetyl cysteine
Study: NCT03443557

Intervention type: OTHER
Intervention: oral nutrition supplement
Description: receiving prescription of oral nutrition supplement during hospitalization
Study: NCT03721445

Intervention type: DEVICE
Intervention: continuous positive airway pressure
Description: Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
Study: NCT00246571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248.
Study: NCT00775203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride (HCl) Extended-Release Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00941434

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF
Description: Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
Study: NCT00232869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent
Description: SMART™ bare-metal stent
Study: NCT02307253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
Description: EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
Study: NCT05343533

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
Study: NCT00628043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta
Description: Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous administration of placebo once-weekly for 12 weeks
Study: NCT00275821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg - 3 times monthly, then quarterly
Description: Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg - 3 times monthly, then quarterly
Description: Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
Study: NCT03022214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
Study: NCT03107195

Intervention type: DRUG
Intervention: Imaging Time
Description: Participants will be asked to be imaged at an additional time point.
Study: NCT03704337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially Available Food Bar
Description: Active

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04708912

Intervention type: OTHER
Intervention: Observation
Description: The study parameters will be obtained at the time of recuirement (Basal)

Intervention type: OTHER
Intervention: Observation
Description: The study parameters will be obtained at the time of recuirement (Basal)

Intervention type: OTHER
Intervention: Observation
Description: The study parameters will be obtained at the time of recuirement (Basal)
Study: NCT00986531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: 2 capsules by mouth for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD8529
Description: 2 capsules by mouth for 3 days
Study: NCT00538681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m², IV, every 21 days, for each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m², IV, every 21 days, for each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po, QD
Study: NCT01905956

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IQP-AK-102
Description: IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
Study: NCT01106755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait training on ground level using BWS
Description: An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait training on ground level using BWS associated to FES
Description: An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
Study: NCT02792257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol (Marinol®)
Description: 5mg - 10mg daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose
Study: NCT04407169

Intervention type: OTHER
Intervention: no intervention
Description: There will be no intervention. It is only an observationnal study

Intervention type: OTHER
Intervention: no intervention
Description: There will be no intervention. It is only an observationnal study
Study: NCT01587950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate
Description: 250 μL of Potassium nitrate solution (either 5% or 2.5%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate
Description: 250 μL of Potassium nitrate solution (either 5% or 2.5%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile Water
Study: NCT02866344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
Study: NCT03412032

Intervention type: OTHER
Group type: OTHER
Intervention: assessment
Description: different assessments in both arms
Study: NCT00275821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3 mg monthly
Description: Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
Study: NCT04551313

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social skill group
Description: We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social skill group
Description: We plan to address basic interactional and conversational skills first, then focus on teaching perspective-taking and theory of mind skills.
Study: NCT01335022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lecture
Description: 6 lectures on cardiovascular disease covering obesity, diet \& exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.